Voyager CEO Al Sandrock outlines a focused strategy: remain specialists in neurology, but broaden the therapeutic modalities (gene therapy, proteins, oligonucleotides). This allows them to pursue well-validated CNS targets that are considered "undruggable" by traditional small molecules, which have historically been the only option for crossing the blood-brain barrier.

Bio Arctic operates a hybrid model. It develops its own neuroscience drugs internally, but also licenses its 'brain transporter' technology as a platform to large pharma partners like Eli Lilly and Novartis. This creates a separate, de-risked revenue stream through milestones and royalties while validating their core technology.

IN8bio chose glioblastoma, a difficult solid tumor, for a strategic reason: to de-risk their platform. By delivering the therapy directly to the brain post-surgery, they could bypass trafficking issues. This ensures that if the therapy fails, it's due to the mechanism itself, not because it didn't reach the target.

The GSK3 inhibitor was developed for CNS diseases, requiring high specificity and the ability to cross the blood-brain barrier. These same pharmaceutical characteristics—potency and lipophilicity—proved highly advantageous for treating cancer, demonstrating an unexpected but effective therapeutic pivot from neuroscience to oncology.

The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.

Bio Arctic is applying its successful Alzheimer's playbook to Parkinson's disease. This involves a highly selective compound that targets only the toxic protein aggregates (alpha-synuclein) while sparing healthy forms, combined with ensuring patients with the correct pathology are selected for trials.

Bio Arctic's "brain transporter" technology is differentiated from competitors. By carefully selecting where its antibody binds on the transferrin receptor, it avoids impacting red blood cells (reticulocytes). This preclinical finding suggests a better safety profile, a key competitive advantage that likely attracts major pharma partners.

The challenge of getting drugs into the brain is being solved, as proven by Denali's recent FDA approval for a drug using its BBB shuttle for Hunter disease. This, combined with Roche's promising Alzheimer's data with a similar technology, provides hard evidence that these platforms work, driving significant M&A and investment activity.

The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.